Prevest Denpro Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Prevest Denpro Ltd filed with BSE on 02 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Prevest DenPro reported FY26 revenue from operations of Rs 71.81 crore, up 13.9% year-on-year, with EBITDA rising 13.3% to Rs 29.62 crore and PAT increasing 12.9% to Rs 20.49 crore. Domestic business grew 9% while exports grew 17.58%, and management described Q4 as more challenging on revenue due to geopolitical tensions but noted profitability growth outpaced revenue growth. Management also discussed the UAE and US subsidiaries, the disinfectant business launch, digital dentistry initiatives, and capacity utilization levels during the Q&A session.
Numbers mentioned
Revenue from operations: INR71.81 crores (FY 2025-26)
p. 4
“Revenue from operation increased by 13.9% to INR71.81 crores compared with INR63.03 crores in financial year 2024-'25.”
Namrata Modi, page 4 of the filed PDF · View the filing
Total income: INR76.72 crores (FY 2025-26)
p. 4
“Total income grew by 14.4% to INR76.72 crores, reflecting broad-based growth across our business segments.”
Namrata Modi, page 4 of the filed PDF · View the filing
EBITDA: INR29.62 crores (FY 2025-26)
p. 4
“EBITDA increased by 13.3% to INR29.62 crores.”
Namrata Modi, page 4 of the filed PDF · View the filing
Profit before tax: INR27.61 crores (FY 2025-26)
p. 4
“Profit before tax grew by 13.9% to INR27.61 crores and profit after tax increased by 12.9% to INR20.49 crores.”
Namrata Modi, page 4 of the filed PDF · View the filing
EBITDA margin: 38.6% (FY 2025-26)
p. 4
“The company maintained healthy profitability with an EBITDA margin of 38.6%, a PBT margin of 36.0% and a PAT margin of 26.7%.”
Namrata Modi, page 4 of the filed PDF · View the filing
Revenue from operations: INR18.94 crores (Q4 FY 2025-26)
p. 5
“Revenue from operation increased by 2.63% to INR18.94 crores, while total income grew by 4.18% to INR20.35 crores.”
Namrata Modi, page 5 of the filed PDF · View the filing
EBITDA: INR8.32 crores (Q4 FY 2025-26)
p. 5
“EBITDA increased by 9.09% to INR8.32 crores.”
Namrata Modi, page 5 of the filed PDF · View the filing
EBITDA margin: 40.87% (Q4 FY 2025-26)
p. 5
“EBITDA margin improved to 40.87%, PBT margin to 38.38% and PAT margin to 28.61%, demonstrating our ability to protect profitability even under difficult market conditions.”
Namrata Modi, page 5 of the filed PDF · View the filing
Overall sales growth: 13.89% (FY 2025-26)
p. 5
“I'm pleased to share that our overall sales grew by 13.89% on a year-on-year basis.”
Vaibhav Munjal, page 5 of the filed PDF · View the filing
US business growth: 37.58% (FY 2025-26 vs prior year)
p. 8
“Last -- in comparison to last year, we have grown the business in U.S. 37.58%, which is included with Axiodent and as well as private labeling”
Namrata Modi, page 8 of the filed PDF · View the filing
Traditional capacity utilization: 67% to 68%
p. 9
“the traditional capacity, the company is working at a capacity utilization of, say, around 67% to 68% of its total installed capacity.”
Vinay Jamwal, page 9 of the filed PDF · View the filing
New production line capacity utilization: 18% to 20%
p. 9
“as far as the new production line is concerned, which includes digital dentistry, resin, disinfectants, oral health and all these, the company is working at, say, around 18% to 20%”
Vinay Jamwal, page 9 of the filed PDF · View the filing
Oradox sales growth: down 2% (FY 2025-26)
p. 10
“We are down by 2%. That is because we couldn't export to the markets in the US.”
Sai Kalyan, page 10 of the filed PDF · View the filing
3D printer sales growth: around 162% (year-on-year)
p. 11
“So, from the last year to this year, we have seen an increase in sales by around 162%”
Sai Kalyan, page 11 of the filed PDF · View the filing
3D resins growth: 40.5% (year-on-year)
p. 11
“Yes, and 3D resins 40.5%.”
Namrata Modi, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Total installed capacity turnover potential — INR125 crores
stated conditionally by Vinay Jamwal
p. 9
“And if the company works with total installed capacity, the total turnover would be around, say, INR125 crores.”
Vinay Jamwal, page 9 of the filed PDF · View the filing
New production line capacity utilization — coming years
stated as an aspiration by Vinay Jamwal
p. 9
“very likely to increase the capacity utilized in the coming years.”
Vinay Jamwal, page 9 of the filed PDF · View the filing
Indigenous 3D printer — totally indigenous 3D printer · by 2028
stated as an aspiration by Sai Kalyan
p. 11
“We are also actively working on the 3D printer project as well, so that we have a totally indigenous 3D printer by 2028.”
Sai Kalyan, page 11 of the filed PDF · View the filing
Digital workflow adoption in dental procedures — at least 40% of all procedures · next 5 years
stated as an aspiration by Sai Kalyan
p. 11
“And we expect in the next 5 years, at least 40% of all procedures, which are done at the dental office will be having a digital workflow.”
Sai Kalyan, page 11 of the filed PDF · View the filing
OEM partnerships — another couple of big companies · next 2 years
stated as an aspiration by Sai Kalyan
p. 12
“And in the next 2 years, we expect to OEM for another big couple of companies.”
Sai Kalyan, page 12 of the filed PDF · View the filing
US business growth — next few years
stated as an aspiration by Namrata Modi
p. 12
“we are very positive and hopeful that in next few years, it will definitely grow more and more because we are aggressively taking part in exhibitions in USA”
Namrata Modi, page 12 of the filed PDF · View the filing
Dubai online sales launch — next month
stated conditionally by Namrata Modi
p. 8
“And next month, most probably, we will start online sale also in Dubai through this subsidiary company.”
Namrata Modi, page 8 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said export growth of 17-18% is strong given geopolitical challenges, and the company's reach across many countries helps offset setbacks in any single region.
Answered by Namrata Modi
Asked by Rahul Sharma: Why has the company's growth rate declined compared to the last 3-4 years?
p. 7
“still, if you see that 17% growth in -- 17.5% growth in export market is very, very satisfactory in the present scenario.”
Namrata Modi, page 7 of the filed PDF · View the filing
Management said they did not have the exact R&D spending figure but described progress including new product launches and import substitution efforts.
Answered by Sai Kalyan
Asked by Rahul Sharma: What percentage of revenue is spent on R&D?
p. 7
“We don't have the exact number yet. I will pass on the exact number to you.”
Sai Kalyan, page 7 of the filed PDF · View the filing
Management said the US subsidiary Axiodent grew significantly and the Dubai subsidiary, opened in February, is building sales presence with online sales expected to start soon.
Answered by Namrata Modi
Asked by Yash Modi: What is the purpose of the UAE and US subsidiaries and how is the Dubai response?
p. 8
“there is a significant sale growth of U.S. market. Last -- in comparison to last year, we have grown the business in U.S. 37.58%”
Namrata Modi, page 8 of the filed PDF · View the filing
Management stated traditional capacity utilization is around 67-68% and new production lines are at 18-20% utilization.
Answered by Vinay Jamwal
Asked by Yash Modi: What is the current capacity utilization at the plant?
p. 9
“the company is working at a capacity utilization of, say, around 67% to 68% of its total installed capacity.”
Vinay Jamwal, page 9 of the filed PDF · View the filing
Management described expanding the distribution network into Tier 2/3 cities, adding sales team members, and increasing the product portfolio with disinfectants and Rotoflex.
Answered by Vaibhav Munjal
Asked by Yash Modi: What steps has the company taken to increase domestic sales?
p. 9
“starting with the expansion of our distribution network in Tier 2, Tier 3 cities. Then we started adding -- last year is when we started adding our sales team members”
Vaibhav Munjal, page 9 of the filed PDF · View the filing
Management said Oradox sales declined 2% due to export disruptions in the US and Dubai but expects new product launches to improve performance.
Answered by Sai Kalyan
Asked by Ajay Shah: How is the Oradox business performing and what is its sales growth?
p. 10
“We are down by 2%. That is because we couldn't export to the markets in the US.”
Sai Kalyan, page 10 of the filed PDF · View the filing
Management said the company has an edge in digital dentistry since MNCs are not fully into that segment yet, and expects strong growth in digital workflow adoption.
Answered by Sai Kalyan
Asked by Ajay Shah: What is the company's competitive position in 3D printing versus MNCs?
p. 11
“when it comes to the digital dentistry, everyone is at the same level. Probably we are slightly ahead than the other MNCs.”
Sai Kalyan, page 11 of the filed PDF · View the filing
Management named Ivoclar, Dentsply and 3Shape as competitors and said lower production costs and OEM partnerships help the company compete.
Answered by Sai Kalyan
Asked by Hussain Rangwalla: Who are the main MNC competitors and how does the company compete?
p. 12
“A major competitors must be like companies like Ivoclar, Dentsply, 3Shape and all these things.”
Sai Kalyan, page 12 of the filed PDF · View the filing
Management said the US business grew 38% this year and expects continued growth from exhibitions and both online and private label channels.
Answered by Namrata Modi
Asked by Ajay Shah: How does management see the US business over the next 2-3 years?
p. 12
“US market, definitely, this year, if the business has been increased by 38%.”
Namrata Modi, page 12 of the filed PDF · View the filing
Risks flagged
Tariff-related developments, geopolitical tensions and conflict disrupting international trade and logistics
p. 3
“The global business environment remained challenging throughout the year, with tariff-related developments, geopolitical tensions and ongoing conflict disrupting international trade, logistics and customer ordering patterns.”
Namrata Modi, page 3 of the filed PDF · View the filing
Delay in UAE subsidiary commercial operations due to geopolitical tensions
p. 4
“the commencement of commercial operations was delayed due to geopolitical tensions and conflict in the Middle East, which impacted overall business activity”
Namrata Modi, page 4 of the filed PDF · View the filing
Q4 revenue challenges from geopolitical tensions and shipping disruption
p. 5
“the fourth quarter was relatively more challenging from a revenue perspective due to high geopolitical tensions, war-related developments and disruption in global shipping and supply chain, which affected customers' ordering patterns and export dispatches.”
Namrata Modi, page 5 of the filed PDF · View the filing
Margin moderation compared to previous year
p. 4
“While margin moderated marginally compared with the previous year, this continued to remain among the strong, reflecting our disciplined approach towards the cost management and operational efficiency.”
Namrata Modi, page 4 of the filed PDF · View the filing
Domestic business impacted by floods and GST changes
p. 10
“The first half of the year for domestic business was not that great because of the GST changes and the disruptions due to major events, like, there were in the first half of quarter of the year, there were floods in Jammu”
Vaibhav Munjal, page 10 of the filed PDF · View the filing
Oradox export disruption due to US regulatory changes and Dubai war situation
p. 10
“US started a new portal called the Modernization of Cosmetic Regulations Act. And the Dubai Municipality and after the war, we couldn't export substantial amounts.”
Sai Kalyan, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.